Contribute
España
Italia
대한민국
日本
Français

Benzinga

Research
My Stocks
Tools
Free Benzinga Pro Trial
SPY
761.930.02%
QQQ
707.830.03%
BTC/USD
77580.670.2431%
DIA
527.670.02%
GLD
396.500.06%
TLT
81.830.05%

Beam Therapeutics Inc

BEAMNASDAQ
Trade with Public
Trade with Public
$29.02
-0.41-1.39%
At close: Sep 1, 5:00 PM EST
$29.03
0.010.03%
After Hours: 7:40 PM EST
OverviewNewsEarnings ForecastEventsPrice TargetsFinancialsSentimentOwnershipCompareOptionsStock Report

Beam Therapeutics Analyst Price Targets

Wall Street analyst price targets and consensus rating for Beam Therapeutics (BEAM).

Price Target Range — 13 Quarters

Analyst Consensus — 18 Analysts

15Buy
3Hold
Consensus RatingBuy# Analysts18Avg. Consensus PT$49Upside to Avg. PT+70.3%

Rating Trend — Last 9 Months

Recent Analyst Actions

See all ratings →
DateFirmAnalystActionRating ChangePrice Target
Aug 25, 2026HC Wainwright & Co.Patrick R. TrucchioMaintainedBuy$80
Jul 8, 2026B of A SecuritiesAlec StranahanMaintainedBuy$47
More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
HC Wainwright & Co. Reiterates Buy on Beam Therapeutics, Maintains $80 Price Target

HC Wainwright & Co. analyst Patrick R. Trucchio reiterates Beam Therapeutics (NASDAQ:BEAM) with a Buy and maintains $80 price target.
Benzinga Newsdesk

PRO
B of A Securities Reiterates Buy on Beam Therapeutics, Maintains $47 Price Target

B of A Securities analyst Alec Stranahan reiterates Beam Therapeutics (NASDAQ:BEAM) with a Buy and maintains $47 price target.
Benzinga Newsdesk

PRO
HC Wainwright & Co. Reiterates Buy on Beam Therapeutics, Maintains $80 Price Target

HC Wainwright & Co. analyst Patrick R. Trucchio reiterates Beam Therapeutics (NASDAQ:BEAM) with a Buy and maintains $80 price target.
Benzinga Newsdesk

PRO
Bernstein Maintains Outperform on Beam Therapeutics, Lowers Price Target to $39

Bernstein analyst William Pickering maintains Beam Therapeutics (NASDAQ:BEAM) with a Outperform and lowers the price target from $40 to $39.
Benzinga Newsdesk

PRO
Citigroup Maintains Buy on Beam Therapeutics, Raises Price Target to $68

Citigroup analyst Samantha Semenkow maintains Beam Therapeutics (NASDAQ:BEAM) with a Buy and raises the price target from $64 to $68.
Benzinga Newsdesk

PRO
RBC Capital Maintains Sector Perform on Beam Therapeutics, Raises Price Target to $26

RBC Capital analyst Luca Issi maintains Beam Therapeutics (NASDAQ:BEAM) with a Sector Perform and raises the price target from $22 to $26.
Benzinga Newsdesk

Data & APIs: Benzinga APIs · Stock News API · Analyst Ratings API · Company Logo API

Market data provided by Benzinga APIs

Connect With Us
instagramlinkedinyoutubeblueskymastodon
About Benzinga
Market Resources
Trading Tools & Education
Ring the Bell
© 2026 Benzinga | All Rights Reserved